Singapore, July 5 -- Taiwan absed Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, has announced that its drug Silmitasertib was again identified as one of the top potential treatments against COVID-19.

The latest international study led by Professor Nevan Krogan of UCSF's Quantitative Biosciences Institute found that the Casein Kinase 2 (CK2) inhibitor, Silmitasertib, displayed robust antiviral activity in treating COVID-19, in vitro. Results were published in the June 28, 2020 issue of the scientific journal, Cell.

The new study revealed startling images that the new coronavirus causes infected cells to sprout tentacles -...